Ibio Inc (IBIO)

$1.16 +0.01 (0.87%)
Market Cap 23.29M
Revenue (ttm) 400,000.00
Net Income (ttm) -18.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,595.00%
Debt to Equity Ratio 0.06
Volume 819,200
Avg Vol 3,702,962
Day's Range N/A - N/A
Shares Out 20.26M
Stochastic %K 9%
Beta 0.93
Analysts Strong Sell
Price Target $3.65

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
suredubb
suredubb Nov. 15 at 3:42 AM
$IBIO love when big investors are involved.. stock will go down at times, but they always support it.. the institutional and insider buying is enough endorsement for me.. next big analyst coverage and this stock flys… when they name a strategic partner soon… boom human trials begin in early 2027
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 15 at 1:36 AM
$IBIO I think I will be here for a while. Selling candles and buying back dips. Smart money is here as well
0 · Reply
CompoundCowboy
CompoundCowboy Nov. 15 at 1:07 AM
$IBIO
0 · Reply
2pumps1dump
2pumps1dump Nov. 14 at 9:17 PM
$IBIO
0 · Reply
vikingpurple
vikingpurple Nov. 14 at 8:44 PM
$IBIO Coming up on 15 years of ownership in the stock. It’s not a pretty sight doing a review.
0 · Reply
Chyeahhh
Chyeahhh Nov. 14 at 8:02 PM
$IBIO didn’t get the move I got long early and got out at 1.24 from 1.18 . Needed to feed up liquidity and I told myself that Friday event thing may be a sell the news. But no it went for a nice move past 1.5 I think. With all the market action bearish lately to look at a chart and it be back to where I got it is supportive of bullish strength. But I think I’ll risk staying on the side again because I need to see more moves to determine if this isn’t dilution of this is strength and Demand supporting the constant cash burn. We will see or this will trade back lower or start to melt from here with later more parabolic vs rate of time move.
1 · Reply
2pumps1dump
2pumps1dump Nov. 14 at 7:30 PM
$IBIO 2 more 13G’s, they’re playing you fools. Added.
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 14 at 3:54 PM
$IBIO They pushed all you rookies Out. Keep chomping at the bit! Add
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 14 at 3:14 PM
$IBIO Come on little women
0 · Reply
suredubb
suredubb Nov. 14 at 3:03 PM
$IBIO bought 14,300 more at open.. 54,013 total time to relax and let IBIO do the work
0 · Reply
Latest News on IBIO
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 2 days ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 30, 2025, 7:00 AM EDT - 15 days ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 23, 2025, 7:00 AM EDT - 22 days ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 21, 2025, 7:00 AM EDT - 24 days ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Sep 5, 2025, 7:30 AM EDT - 2 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio Announces Closing of $50 Million Public Offering

Aug 25, 2025, 7:00 AM EDT - 2 months ago

iBio Announces Closing of $50 Million Public Offering

iBio Announces Pricing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 3 months ago

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Proposed Public Offering

Aug 18, 2025, 4:01 PM EDT - 3 months ago

iBio Announces Proposed Public Offering

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 24, 2025, 7:00 AM EDT - 5 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 23, 2025, 4:15 PM EDT - 5 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 16, 2025, 7:00 AM EDT - 5 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025, 8:00 AM EDT - 6 months ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 7 months ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 29, 2025, 1:43 PM EDT - 7 months ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 22, 2025, 8:00 AM EDT - 7 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Apr 7, 2025, 7:00 AM EDT - 7 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 9 months ago

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 9 months ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Jan 2, 2025, 7:00 AM EST - 11 months ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio to Participate in Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

iBio to Participate in Upcoming Investor Conferences

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 1 year ago

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 1 year ago

iBio stock nearly tripled on Wednesday: here's why

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 27, 2024, 7:00 AM EDT - 1 year ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 1 year ago

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 26, 2024, 7:45 AM EST - 1 year ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 1 year ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 27, 2023, 8:00 AM EDT - 2 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

iBio Forges Research Collaboration with the National Institutes of Health

Jun 12, 2023, 4:15 PM EDT - 2 years ago

iBio Forges Research Collaboration with the National Institutes of Health

iBio to Participate in the JMP Securities Life Sciences Conference

May 9, 2023, 4:30 PM EDT - 2 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Apr 4, 2023, 4:05 PM EDT - 2 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Mar 31, 2023, 8:10 AM EDT - 2 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Feb 16, 2023, 4:48 PM EST - 2 years ago

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Dec 9, 2022, 4:05 PM EST - 3 years ago

iBio Announces Closing of $3.5 Million Underwritten Public Offering

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

Dec 6, 2022, 11:27 PM EST - 3 years ago

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

iBio Announces Proposed Underwritten Public Offering

Dec 6, 2022, 4:01 PM EST - 3 years ago

iBio Announces Proposed Underwritten Public Offering

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

Dec 5, 2022, 8:00 AM EST - 3 years ago

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

iBio Announces CEO Departure

Dec 2, 2022, 4:30 PM EST - 3 years ago

iBio Announces CEO Departure

suredubb
suredubb Nov. 15 at 3:42 AM
$IBIO love when big investors are involved.. stock will go down at times, but they always support it.. the institutional and insider buying is enough endorsement for me.. next big analyst coverage and this stock flys… when they name a strategic partner soon… boom human trials begin in early 2027
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 15 at 1:36 AM
$IBIO I think I will be here for a while. Selling candles and buying back dips. Smart money is here as well
0 · Reply
CompoundCowboy
CompoundCowboy Nov. 15 at 1:07 AM
$IBIO
0 · Reply
2pumps1dump
2pumps1dump Nov. 14 at 9:17 PM
$IBIO
0 · Reply
vikingpurple
vikingpurple Nov. 14 at 8:44 PM
$IBIO Coming up on 15 years of ownership in the stock. It’s not a pretty sight doing a review.
0 · Reply
Chyeahhh
Chyeahhh Nov. 14 at 8:02 PM
$IBIO didn’t get the move I got long early and got out at 1.24 from 1.18 . Needed to feed up liquidity and I told myself that Friday event thing may be a sell the news. But no it went for a nice move past 1.5 I think. With all the market action bearish lately to look at a chart and it be back to where I got it is supportive of bullish strength. But I think I’ll risk staying on the side again because I need to see more moves to determine if this isn’t dilution of this is strength and Demand supporting the constant cash burn. We will see or this will trade back lower or start to melt from here with later more parabolic vs rate of time move.
1 · Reply
2pumps1dump
2pumps1dump Nov. 14 at 7:30 PM
$IBIO 2 more 13G’s, they’re playing you fools. Added.
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 14 at 3:54 PM
$IBIO They pushed all you rookies Out. Keep chomping at the bit! Add
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 14 at 3:14 PM
$IBIO Come on little women
0 · Reply
suredubb
suredubb Nov. 14 at 3:03 PM
$IBIO bought 14,300 more at open.. 54,013 total time to relax and let IBIO do the work
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 14 at 2:41 PM
$IBIO Lots are buying off this bottom. Before she pops and it’s too late
0 · Reply
Rower5oh
Rower5oh Nov. 14 at 12:49 PM
$IBIO Bought more this morning. All I know is that this company is worth a lot more than the current market cap
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 14 at 12:33 PM
$IBIO Shes going to bounce off this bottom. I see this before The technical point up 👆
0 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 14 at 12:31 PM
$IBIO That’s how you do it As long as they don’t RS you will be fine. You need nuts 🥜 in this game.
0 · Reply
2pumps1dump
2pumps1dump Nov. 14 at 11:47 AM
$IBIO 13G out, I’m loading more down here!
0 · Reply
Bigbut
Bigbut Nov. 14 at 2:58 AM
$IBIO beep beep beep Now’s the time If you seen my post, you know what that means If you’ve never seen my posts, the BUT stands for back up the truck
1 · Reply
flawlesssqueeze
flawlesssqueeze Nov. 14 at 12:20 AM
$IBIO strong FP&A is healthy!
0 · Reply
FullThrottle1
FullThrottle1 Nov. 13 at 10:52 PM
$IBIO Forever a penny stock….cant stop laughing at the lack of success here.
1 · Reply
reces1
reces1 Nov. 13 at 10:35 PM
$IBIO Waiting on $1.00. Management will get us there!
1 · Reply
IBIO_KEVINTL
IBIO_KEVINTL Nov. 13 at 6:42 PM
$IBIO Pop goes the bubble Not going anywhere But lots of stock on sale damn Buy up look at hood look at soun
0 · Reply
suredubb
suredubb Nov. 13 at 5:00 PM
$IBIO i bought more, but management needs to clean it up…. horrible update of all the same stuff we already know just say presentations went great… say lots of good meetings.. name one of their strategic partners.. easy to take care of shareholders
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Nov. 13 at 4:36 PM
$IBIO ya’ll are soft
0 · Reply